Will pemigatinib be included in medical insurance in 2024?

Pemigatinib (Pemigatinib) is a selective FGFR1-3 inhibitor with potent anti-tumor activity and the ability to inhibit FGFR-mediated tumor invasion and progression. In the FIGHT-202 trial, pemetinib was studied at a dose of 13.5 mg once daily for the first 14 days of a 21-day cycle in patients with previously treated locally advanced or metastatic cholangiocarcinoma (CCA), FGFR2 fusions, or rearrangements. The results showed that the objective response rate of pemetinib was 37% (95% confidence interval 27.94–46.86%), and the median response duration was 9.13 months. month (95% confidence interval is 6.01–14.49 months), and the disease control rate82% (95% confidence interval is 74–89%). The treatment was well tolerated and had a manageable safety profile.

The original drug of pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The specific time of entering the medical insurance is not yet clear. Patients can consult the local medical insurance bureau or hospital to obtain relevant information. The price of each box of 9mg*14 tablets may be around 50,000 yuan, which is expensive. The original drug Pemetinib currently on the market overseas, with a specification of 13.5mg*14 tablets, may cost around RMB 70,000 per box (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold abroad. For example, the price of 4.5mg*14 tablets per box produced by a Laos pharmaceutical factory may be around 1,000 yuan (the price may fluctuate due to exchange rates).